CytRx announces positive updated results from its pivotal Phase 3 clinical trial evaluating aldoxorubicin compared to investigators choice in patients with relapsed or refractory soft tissue sarcomas
Font size: A | A | A
undefined undefined | Briefing.com
The study, which enrolled 433 patients, demonstrated a statistically significant improvement in progression-free survival (PFS) between aldoxorubicin and investigator's choice therapy in 246 patients with leiomyosarcoma and liposarcoma, (p=0.007). The hazard ratio (HR) was 0.62 (95% CI 0.44-0.88), representing a 38% reduction in the risk of tumor progression for patients receiving aldoxorubicin versus investigator's choice. Leiomyosarcoma and liposarcoma are the two most common types of STS and accounted for 57% of the patients enrolled in the trial.
" A rich man is not the one with the most! He is the one that needs the least!"
